ASP Isotopes offers high-risk, high-upside exposure to Western isotope independence, but the investment case hinges on proving commercial-scale enrichment in 2026.
Overview
ASP Isotopes is transitioning from R&D venture to commercial producer of geopolitically sensitive enriched isotopes and specialty gases. Based in Dallas with core operations in South Africa, it serves semiconductor, radiopharma, nuclear fuel, industrial gas, and helium markets through Specialist Isotopes, Quantum Leap Energy, and Renergen assets. The company’s appeal lies in proprietary enrichment technology, scarce material supply, and Western supply-chain resilience. Near-term revenue currently comes from radiopharmacy and gas assets, while the core upside depends on successful commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 beginning in 2026.